CD176 antibody

Catalog No. ABIN6296729

The Mouse Monoclonal anti-CD176 antibody has been validated for IHC and IF. It is suitable to detect CD176 in samples from Human, Mouse and Rat.

Quick Overview for CD176 antibody (ABIN6296729)

Target: CD176 (Thomsen Friedenreich Antigen (CD176))

Reactivity: Human, Mouse, Rat

Host: Mouse

Clonality: Monoclonal

Conjugate: This CD176 antibody is un-conjugated

Application: Immunohistochemistry (IHC), Immunofluorescence (IF)

Product Details anti-CD176 Antibody

Purpose: Mouse anti-Human/Mouse/Rat Thomsen-Friedenreich Antigen Antibody [Sodium Azide Free]

Specificity: Cell surface

Purification: Neuraminidase-treated human red blood cells were used as the immunogen for the Thomsen-Friedenreich Antigen antibody.

Immunogen: Neuraminidase-treated human red blood cells were used as the immunogen for the Thomsen-Friedenreich Antigen antibody.

Application Details

Application Notes: Immunofluorescence: 0.5-1 μg/mL
Immunohistochemistry (FFPE): 0.5-1 μg/mL for 30 min at RT

Restrictions: For Research Use only

Handling

Buffer: In 1X PBS, BSA free, sodium azide free

Preservative: Azide free

Storage: 4 °C,-20 °C

Storage Comment: 2-8°C. The azide-free format should be aliquoted and stored at -20°C or colder.

Target Details for CD176

Target: CD176 (Thomsen Friedenreich Antigen (CD176))

Alternative Name: Thomsen-Friedenreich Antigen

Background:

Target Description: Recognizes a disaccharide epitope, Gal1-3GalNAc, of Thomsen-Friedenreich (TF) antigen. It is specific for both anomeric forms of the disaccharide (TF and TF, including related structures on the glycolipid) and shows no cross-reactivity with sialylated glycophorin. The Thomsen-Friedenreich antigen acts as an oncofetal antigen, with low expression in normal adult tissues but increasing to fetal levels of expression in hyperplasia or malignancy. It is considered as a pan-carcinoma marker. During metastasis, the ability of malignant cells to form multicellular aggregates via homotypic or heterotypic aggregation and their adhesion to the endothelium are critical. The tumor-associated carbohydrate Thomsen-Friedenreich antigen (Gal-GalNAc) is involved in tumor cell adhesion and tissue invasion. It also causes an immune response, and overexpression of the antigen causes cancer cells to be more sensitive to natural killer cell lysis. The Thomsen-Friedenreich antigen is suppressed in normal healthy cells and represents one of the few chemically well-defined antigens associated with tumor malignancy. The presence of the Thomsen-Friedenreich antigen on the surface of cancer cells may result from a divergence from the normal pathway for O-linked glycosylation in these cells, most likely caused by inappropriate localization of the enzymes involved in synthesis of the disaccharide.